肝硬化的治疗进展

被引：97

作者：

张静雯

时永全

韩英

机构：

[1] 第四军医大学西京消化病医院肿瘤生物学国家重点实验室

来源：

临床肝胆病杂志 | 2015年 / 31卷 / 03期

关键词：

肝硬化; 治疗; 综述;

D O I：

暂无

中图分类号：

R575.2 [肝硬变];

学科分类号：

100201 [内科学];

摘要：

肝硬化是由各种因素导致慢性肝损害的一类晚期肝纤维化疾病。简述了肝硬化的病因及相关并发症的治疗进展,指出肝移植作为治疗肝硬化唯一有效的治疗手段,但却受到供肝及费用等问题限制,而干细胞具有治疗肝硬化的巨大潜力,成为研究热点,但其作用机制尚未明确,仍有很多问题尚未解决。

引用

页码：465 / 468

页数：4

共 18 条

[1]

Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis [J].

Mandorfer, Mattias ;

Bota, Simona ;

Schwabl, Philipp ;

Bucsics, Theresa ;

Pfisterer, Nikolaus ;

Kruzik, Matthias ;

Hagmann, Michael ;

Blacky, Alexander ;

Ferlitsch, Arnulf ;

Sieghart, Wolfgang ;

Trauner, Michael ;

Peck-Radosavljevic, Markus ;

Reiberger, Thomas .

GASTROENTEROLOGY, 2014, 146 (07) :1680-+

[2]

Bone Marrow–Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence; Cellular Mechanisms; and Implications for the Treatment of Hepatocellular Carcinoma.[J].Jeffrey M. Vainshtein;Rafi Kabarriti;Keyur J. Mehta;Jayanta Roy-Chowdhury;Chandan Guha.International Journal of Radiation Oncology; Biology; Physics.2014, 4

[3]

l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials [J].

Bai, Ming ;

Yang, Zhiping ;

Qi, Xingshun ;

Fan, Daiming ;

Han, Guohong .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (05) :783-792

[4]

Letter in Response to the Recently Published Review: Hyponatremia in Cirrhosis and End-Stage Liver Disease-Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan [J].

Abhyankar, A. ;

Robson, S. C. ;

Tapper, E. B. ;

Bonder, A. .

DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (03) :889-890

[5]

Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study [J].

Guevara, Monica ;

Terra, Carlos ;

Nazar, Andre ;

Sola, Elsa ;

Fernandez, Javier ;

Pavesi, Marco ;

Arroyo, Vicente ;

Gines, Pere .

JOURNAL OF HEPATOLOGY, 2012, 57 (04) :759-765

[6]

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.[J].Patrick Marcellin;Edward Gane;Maria Buti;Nezam Afdhal;William Sievert;Ira M Jacobson;Mary Kay Washington;George Germanidis;John F Flaherty;Raul Aguilar Schall;Jeffrey D Bornstein;Kathryn M Kitrinos;G Mani Subramanian;John G McHutchison;E Jenny Heathcote.The Lancet.2012,

[7]

Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study [J].

Fernandez, Javier ;

Acevedo, Juan ;

Castro, Miriam ;

Garcia, Orlando ;

Rodriguez de Lope, Carlos ;

Roca, Daria ;

Pavesi, Marco ;

Sola, Elsa ;

Moreira, Leticia ;

Silva, Anibal ;

Seva-Pereira, Tiago ;

Corradi, Francesco ;

Mensa, Jose ;

Gines, Pere ;

Arroyo, Vicente .

HEPATOLOGY, 2012, 55 (05) :1551-1561

[8]

Risk factors for resistance to ceftriaxone and its impact on mortality in community; healthcare and nosocomial spontaneous bacterial peritonitis.[J].Xavier Ariza;José Castellote;Jaime Lora-Tamayo;Anna Girbau;Sílvia Salord;Rosa Rota;Javier Ariza;Xavier Xiol.Journal of Hepatology.2011, 4

[9]

Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection [J].

Cholongitas, E. ;

Theocharidou, E. ;

Goulis, J. ;

Tsochatzis, E. ;

Akriviadis, E. ;

Burroughs, A. K. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (06) :634-646

[10]

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C [J].

Rao, Gowtham A. ;

Pandya, Prashant K. .

GASTROENTEROLOGY, 2011, 140 (01) :144-+

← 1 2 →